-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
USA stage 4 stomach cancer patient given chemo option for rest of life (18 months) self advocate for cart T cell clinical trial and see tumor shrunk
- Thread starter ginfreely
- Start date
Lucky woman qualified for the cart T cell clinical trial that requires patient to test positive for claudin.
Abstract
Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment of solid tumors, including advanced gastric cancer (GC), has proven more challenging due to on-target off-tumor toxicities, poor tumor T-cell infiltration, inefficient CAR T-cell expansion, immunosuppressive tumor microenvironments, and demanding preconditioning regimens. We report the exceptional results of autologous Claudin18.2-targeted CAR T cells (CT041) in a patient with metastatic GC, who had progressed on four lines of combined systemic chemotherapy and immunotherapy. After two CT041 infusions, the patient had target lesion complete response and sustained an 8-month overall partial response with only minimal ascites. Moreover, tumor-informed circulating tumor DNA (ctDNA) reductions coincided with rapid CAR T-cell expansion and radiologic response. No severe toxicities occurred, and the patient's quality of life significantly improved. This experience supports targeting Claudin18.2-positive GC with CAR T-cell therapy and helps to validate ctDNA as a biomarker in CAR T-cell therapy. Clinical Insight:Claudin18.2-targeted CAR T cells can safely provide complete objective and ctDNA response in salvage metastatic GC.
In the first place you have to be lucky to be in USA to qualify for testing for car T cell clinical trial. Spore people have to be able to afford to pay for it. Got such good deal free clinical trial for super expensive car T cell?
Again angmoh the best even for stomach cancer that is considered rare cancer in USA.
Lucky woman said she also participated in monoclonal antibody clinical trial.
And she also said she then did chemo plus immunotherapy after that. So lucky to qualify for two clinical trials and immunotherapy. Looks like all costs covered, never see USA or Europe cancer YouTubers worry or complain costs of immunotherapy. Aren’t they expensive cancer drugs?
Similar threads
